B+
Bull case
30%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
GENB
Generate BiomedicinesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
GB-5267 reached first-patient dosing, GB-4362 entered its first cohort, and the company-released COPD poster reported sustained pharmacodynamic biomarker reductions after one GB-0895 dose. Those are execution and early biological signals, not clinical efficacy proof.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.5.
What can break
Cash and marketable securities fell from $516.6 million at March 31 to $457.4 million at June 30; management projects runway into the first half of 2028 and expects additional capital for long-term operations. [#SEC-8K-2026-08-06] SEC earnings exhibit
Momentum
10
Value
46
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $22.00 · Bear $8.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $27.00
Why
Momentum10 · Δ7d -0.1
Value46 · Δ7d +0.0
Sentiment77 · Δ7d -2.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -2.5.
Contradictions & invalidation
- • Cash and marketable securities fell from $516.6 million at March 31 to $457.4 million at June 30; management projects runway into the first half of 2028 and expects additional capital for long-term operations. [#SEC-8K-2026-08-06] SEC earnings exhibit
- • Phase 3 recruitment, GB-4362 tolerability, and GB-5267 cell-therapy manufacturing and safety remain material execution risks.
- • Phase 3 asthma efficacy remains unproven, the COPD poster reports blinded early-stage data, and the October 1 GB-5267 milestone starts a safety-focused Phase 1 study.
Catalyst clock
2026-10-01
GB-5267 first patient dosed
Lead driver: Sentiment · See AI snapshot
Momentum
10
8% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-44.7
Value
46
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
0.0
Sentiment
77
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.5
Δ21d
+1.1
Why this grade
Composite grade B. Momentum 10.0 / Value 46.5 / Sentiment 76.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$1.59B
Beta
-
Shares Out
128.35M
P/E (TTM) · Derived
-6.3
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-37.7%
EPS YoY
-73.0%
Gross Margin
-
Op Margin
-
Net Debt
-$153.31M
Current Ratio
8.30
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data